|
CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on CVD Risk and Health in Postmenopausal Phytoestrogen Users conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical research trials and CVD Risk and Health in Postmenopausal Phytoestrogen Users health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including CVD Risk and Health in Postmenopausal Phytoestrogen Users. CVD Risk and Health in Postmenopausal Phytoestrogen Users Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a CVD Risk and Health in Postmenopausal Phytoestrogen Users clinical trial. Participants oftentimes recieve the most expert healthcare available for their CVD Risk and Health in Postmenopausal Phytoestrogen Users condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CVD Risk and Health in Postmenopausal Phytoestrogen Users  CVD Risk and Health in Postmenopausal Phytoestrogen Users
CVD Risk and Health in Postmenopausal Phytoestrogen Users
For Condition: Bone Diseases,Cardiovascular Diseases,Coronary Disease,Depression,Heart Diseases,Myocardial Ischemia,Osteoporosis,Postmenopause
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.
Details: BACKGROUND: Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen. DESIGN NARRATIVE: Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo goups are performed before and after adjustment and stratification for potentially confounding covariates. The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 45 Years/74 Years
Genders: Female
Protocol Entry Criteria: Postmenopausal women, ages 45 to 74.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DonnaKritz-Silverstein, , University of California at San Diego
Additional Information:
Study ID Numbers: 116;
Study Start Date: April 1997
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000613
Other Cardiovascular Diseases Studies:
1. Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause
2. Women's Health Trial: Feasibility Study in Minority Populations
3. Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)
4. Lifestyle Management for Women with CHD and NIDDM
5. Women's Angiographic Vitamin and Estrogen Trial (WAVE)
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
CVD Risk and Health in Postmenopausal Phytoestrogen Users
|
|
|
|
|
|
|
|
